A Phase Ib/II multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)

Gary Middleton, James Spicer, Burak Aktas, Habana Dinizulu, Richard H Wilson, David J Harrison, Elisabeth Oelmann, Jeff Bloss, Fiona Thistlethwaite
doi: https://doi.org/10.1101/2024.11.07.24316829

Data Availability

All data produced in the present study are contained in the manuscript and supplementary data

Back to top
Posted November 08, 2024.
Download PDF

Supplementary Material

Data/Code
Email
A Phase Ib/II multi-arm, dose finding and expansion study of a novel thymidylate synthase inhibitor with immune modulating properties, NUC-3373, in combination with pembrolizumab or docetaxel in patients with advanced solid tumors (NuTide:303)
Gary Middleton, James Spicer, Burak Aktas, Habana Dinizulu, Richard H Wilson, David J Harrison, Elisabeth Oelmann, Jeff Bloss, Fiona Thistlethwaite
medRxiv 2024.11.07.24316829; doi: https://doi.org/10.1101/2024.11.07.24316829
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area